Loading
Every dated change on the records linked to ALK-positive non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
First-line ALK+ NSCLC
Median progression-free survival 34.
Confirmed objective response rate 45% (90 mg) and 54% (180 mg after a 7-day 90 mg lead-in); median progression-free survival 9.
Median progression-free survival 16.
Stopped at the second interim analysis for a large progression-free survival advantage of alectinib over crizotinib.
A milestone in how this cancer is treated.